
Reta$125

From the lab.
To a bigger conversation.
Categories describe areas of research and proposed benefits. A result in cells or animals is a starting point for exploration; it does not establish the same effect in people.
Community perspectives capture ideas and experiences from the wider conversation. Their claims remain attributed to their authors. Open any source to explore its methods, context, and conclusions.
3 sources for “retatrutide”
Research paperIn 338 adults, retatrutide produced substantial weight reduction over 48 weeks. The highest treatment group averaged 24.2% weight loss versus 2.1% with placebo.
Phase 2 trial; gastrointestinal events were common and heart rate increased during treatment.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine, 2023
Community perspectiveCarrie MacMillan asks Yale obesity specialists why combining hormone signals may improve metabolic treatment. Retatrutide illustrates the move beyond two receptors, while muscle, bone, and tolerability shape the questions researchers ask next.
An institutional explainer featuring clinician interpretation; it does not provide a head-to-head trial of every therapy discussed.
Beyond GLP-1s: Combination Therapy, New Hormones Reshape Obesity Treatment
Carrie MacMillan · Yale Medicine, 2026
Research paperIn 98 participants with fatty liver, retatrutide substantially reduced MRI-measured liver fat. The largest average relative reduction was 82.4% at 24 weeks.
This measures liver fat, not biopsy-confirmed reversal of liver fibrosis; it is a substudy of the obesity trial.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal et al. · Nature Medicine, 2024